3646 results for «467»
3646 results
Shaping the future: top innovations at PCR London Valves 2025
16 Nov 2025 – From PCR London Valves 2025
Highlighting transformative innovations from PCR London Valves 2025, this session features advanced technologies such as the Luna TMVR with its unique intuitive design, the novel Tripair technology for tricuspid therapy, and insights into right heart remodeling following transcatheter tricuspid valve interventions with the DUO system, showcasing...
Featured research: clinical outcomes and real-world evidence in modern TAVI practice
16 Nov 2025 – From PCR London Valves 2025
This session presents featured research on Transcatheter Aortic Valve Implantation (TAVI), analyzing clinical impacts of prosthesis oversizing, same-day discharge experiences, and comparative outcomes of intra-annular versus supra-annular self-expanding valves. It also reviews nationwide TAVR data from Germany and meta-analyses assessing TAVI performance in centers without on-site...
Featured research: innovations, safety and evolving pathways in modern TAVI care
16 Nov 2025 – From PCR London Valves 2025
This session addresses contemporary challenges in TAVI, including management of acute valve syndrome through service innovations and the application of Valvosoft non-invasive ultrasound therapy in severe aortic stenosis. It also explores complications such as infective endocarditis post-TAVI, evaluates the feasibility of same-day discharge protocols, and assesses...
TAVI and coronary artery disease
16 Nov 2025 – From PCR London Valves 2025
This session focuses on the interplay between TAVI and coronary artery disease, discussing high-risk TAVR cases requiring complex left main PCI with prophylactic ECMO support. It provides guidance on timing and strategies for managing concomitant coronary artery disease in TAVI patients, addressing the critical decision-making process...
Transcatheter tricuspid valve replacement - LIVE Case
18 Nov 2025 – From PCR London Valves 2025
Live case: An 86-year-old male, with a history of PPM, permanent AF, CKD stage 3, and moderately impaired LV function (50–55%), presented with symptomatic torrential mixed TR (tricuspid annular dilatation and pacing lead on the septal leaflet). An Evoque valve was implanted under fluoroscopy and TEE...
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/congress-coverages/esc/2025/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)